获得DMR的慢性粒细胞白血病患者停用二代TKI的系统回顾和meta分析
摘要
关键词
全文:
PDF参考
[1]张之南,都玉书,赵永强等.血液病学[M].北京:人民卫生出版社,2003. [2]Anonymous. National-Comprehensive-Cancer Network. Chronic myelogenous leukemia. NCCN Clinical Practice Guidelines in Oncology.2019. [3]Rosti G,Castagnetti F,Gugliotta G,Baccarani M.Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?[J].Nat Rev Clin Oncol,2017(14):141-54. [4]Zaidi U,Kaleem B,Borhany M,Maqsood S,Fatima N,Sufaida G,et al.Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients[J].Cancer Manag Res,2019(11):1493-502. [5]Rosti G,Castagnetti F,Gugliotta G,Palandri F,Baccarani M.Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev. 2012; 38: 241-8. 6. Keating GM, Lyseng-Williamson KA, McCormack PL, Keam SJ. Dasatinib: a guide to its use in chronic myeloid leukemia in the EU[J].BioDrugs,2013(27):275-9. [7]Cross N,White HE,Colomer D,Ehrencrona H,Foroni L,Gottardi E,et al.Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia[J].Leukemia,2015(29):999-1003. [8]Oncology NCPGi.Chronic Myelogenous Leukemia.V1.2020. [9]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration[J].BMJ,2009(339):2700. [10]GA S-B-O-CW.The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses,2009. [11]DerSimonian R, Laird N. Meta-analysis in clinical trials[J].Control Clin Trials,1986(7):177-88. [12]Thompson SG,Deeks JJ,Higgins JP.Measuring inconsistency in meta-analyses[J].Br Med J,2003(327):557. [13]Hochhaus A,Shah NP,Cortes JE,Baccarani M,Bradley-Garelik MB,Dejardin D,et al.Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up[J].American Society of Clinical Oncology.2012. [14]Kadowaki N,Kawaguchi T,Kuroda J,Nakamae H,Matsumura I,Miyamoto T,et al.Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: a multicenter phase 2 stop nilotinib (Nilst) trial[J].Am Soc Hematology,2016. [15]Saglio G,Masszi T,Gomez Casares M,Hellmann A,Stentoft J,Conneally E,et al.Results from ENESTfreedom: treatment-free remission (Tfr) following frontline nilotinib (Nil) in patients (Pts) with chronic myeloid leukemia in chronic phase (Cml-Cp). Haematologica: FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY; 2016,240-1. [16]Hughes T, Boquimpani C, Takahashi N, Benyamini N, Clementino N, Shuvaev V, et al. Results from enestop: treatment-free remission (Tfr) following switch to nilotinib (Nil) in patients (Pts) with chronic myeloid leukemia in chronic phase (Cml-Cp). Haematologica: FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY; 2016,65-2. [17]Takahashi N, Nishiwaki K, Nakaseko C, Wakita H, Sano K, Ohwada C, et al. Successful treatment free remission in CML after 2 year consolidation with nilotinib of an MR4. 5 response level achieved originally with imatinib treatment: first report from STAT2 trial in Japan. Haematologica: FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY; 2016,61-2. [18]Hochhaus A, Masszi T, Giles F, Radich J, Ross D, Casares MG, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study[J].Leukemia,2017(31):1525. [19]Takahashi N,Nakaseko C,Nishiwaki K,Wakita H. Two-year consolidation by nilotinib is associated with successful treatment free remission in chronic myeloid leukemia with MR4. 5: subgroup analysis from STAT2 trial in Japan[J].Am Soc Hematology,2016. [20]Shah NP,Gutiérrez JVG,Jiménez-Velasco A,Larson SM,Saussele S,Rea D,et al.Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE)[J].Am Soc Hematology,2017. [21]Kumagai T,Nakaseko C,Nishiwaki K,Yoshida C,Ohashi K, Takezako N,et al.Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese trial (D-STOP Trial). Am Soc Hematology; 2016,A791. [22]Kadowaki N, Kawaguchi T, Kuroda J, Nakamae H, Matsumura I, Miyamoto T, et al. Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: a multicenter phase 2 stop nilotinib (Nilst) trial. Am Soc Hematology; 2016,A790. [23]Hughes T,Boquimpani C,Takahashi N,Benyamini N,Clementino N,Shuvaev V,et al. Durable treatment-free remission after stopping secondline nilotinib in patients with chronic myeloid leukemia in chronic phase: enestop 96-wk update[J].Haematologica,2017(102):75. [24]Clark R,Polydoros F,Apperley J,Pocock C,Smith G,Byrne J,et al.Initial reduction of therapy before complete withdrawal improves the chance of successful treatment discontinuation in chronic myeloid leukaemia (CML): year 2 results in the British DESTINY study. Haematologica: FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY; 2017,151. [25]Fava C, Rege-Carmbrin G, Dogliotti I, Cerrano M, Berchialla P, Rosti G, et al. Observational study of CML Italian patients who discontinued TKIs. Am Soc Hematology; 2017. [26]Richter J,Mahon F,Guilhot J,Hjorth-Hansen H, Almeida A,Janssen J,et al. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial[J].Haematologica. 2016(101):22-3. [27]Nicolini FE, Alcazer V, Dulucq S, Balsat M, Labussiere H, Lequeu H, et al. Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML. Am Soc Hematology; 2016. [28]Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia[J].Cancer,2017(123):4403-10. [29]Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study[J].Blood,2017(129):846-54. [30]Ross DM, Masszi T, Gomez Casares MT, Hellmann A, Stentoft J, Conneally E, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study[J].J Cancer Res Clin Oncol,2018(144):945-54. [31]Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, et al. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment[J].Clin Lymphoma Myeloma Leuk,2018(18)353-60. [32]Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan[J].Haematologica,2018(103):1835-42. [33]Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study[J].Ann Intern Med,2018(168):461-70. [34]Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis[J].Leuk Lymphoma,2016(57):1300-10. [35]Chen KK,Du TF,Xiong PS,Fan GH,Yang W.Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis[J].Front Oncol,2019(9):372. [36]El Eit R, Itani AR, Nassar F, Rasbieh N, Jabbour M, Santina A, et al. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors[J].Cancer,2019(125):2818-28. [37]Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy[J].Mol Oncol,2010(4):443-50.
(81 摘要 Views, 50 PDF Downloads)
Refbacks
- 当前没有refback。